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every 1 000 live births, a mere 10% reduction in 16 years. The 
corresponding figures for North Africa were 88 and 35 (i.e. 
60% reduction). In addition, a woman’s lifetime risk of dying 
during pregnancy and childbirth was 1 in 16 in sub-Saharan 
Africa; compared with 1 in 3 800 in the developed world. Most 
maternal deaths in sub-Saharan Africa resulted from maternal 
haemorrhage, hypertensive disorders of pregnancy, sepsis, 
abortion, and obstructed labour.2,3 Most of these deaths could 
have been prevented through appropriate reproductive health 
services before, during and after pregnancy, and through life-
saving interventions when complications occur.4,5 
Sub-Saharan Africa can increase its pace towards achieving 
health MDG if efforts to prevent death and disability are 
tailored to local conditions, given that the causes of death and 
disability vary considerably.2,3,6 Choice of health interventions 
and policies should be based on solid scientific evidence, and, 
where it is lacking, we must invest in research.7 Such well-
informed selection and implementation of effective health care 
interventions and policies requires close collaboration between 
policy-makers and researchers. 
The SUPPORT (SUPporting Policy-relevant Reviews and 
Trials) Collaboration is an example of cooperative partnership 
between researchers and policy-makers in low- and middle-
income countries, which started in October 2006. SUPPORT 
(www.support-collaboration.org) involves partner institutions 
in sub-Saharan Africa, Latin America, Europe and North 
America, and aims to improve the use of reliable research 
evidence in decisions on maternal and child health, and to 
help fill in the gaps where there is a lack of rigorous evidence. 
The partner institutions (including the Medical Research 
Council of South Africa) are preparing summaries of current 
best evidence on the effectiveness of relevant interventions in 
a way that is easily accessible to decision makers, developing 
tools to support access to and use of research evidence to 
inform policy decisions, supporting the conduct of pragmatic 
trials of interventions when reliable evidence is lacking, and 
exploring appropriate ways to disseminate these tools and 
provide support for the appropriate use of research evidence. 
The structured summaries will be available by December 2007 
and SUPPORT partners conducted a policy-maker workshop 
in Rosario (Argentina) in November 2006 and have planned 
others in Harare (Zimbabwe) and Cape Town (South Africa) 
in September and November 2007 respectively. Workshops 
comprise interactive presentations and small group sessions 
during which policy-makers develop skills on how to frame 
a health problem, identify a systematic review or trial that 
addresses the problem, and assess the quality and local 
applicability of the systematic review or trial. Each workshop is 
planned and facilitated by both policy-makers and researchers, 
ends with an evaluation, and empowers policy-makers to 
become informed users of research-based evidence. This 
knowledge-translation project provides a model of how multi-
national collaborations can be configured and how efficiencies 
can be gained from cross-continental linkages.  
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Why no autopsies on marathon deaths?
To the Editor: The July 2007 SAMJ featured a report on 
the deaths of two Comrades Marathon runners.1  I agree 
with Mayosi of Groote Schuur Hospital that postmortem 
examinations should be performed on such cases to establish 
the cause of death with certainty, in so far as it is possible, 
because of implications for the surviving next of kin. 
We expected that the Forensic Pathology Services in Durban 
would receive these cases, but neither was referred.  Both 
deaths can be considered unexpected and unexplained sudden 
deaths, since there are no clear clinical diagnoses (owing to 
very short survival of only one of them) and both individuals 
were relatively young.  However, the decision to request 
an autopsy is the duty of the clinician responsible for the 
patient.  It is likely that both these deaths were considered and 
registered as natural deaths.
There is capacity for diagnostic autopsy examinations on 
sudden unexpected deaths mainly in the academic forensic 
pathology centres.  Where the source of the case is not a 
public establishment, there is little provision in the academic 
anatomical pathology unit served by that establishment (now 
under the National Health Laboratory Service) for a diagnostic 
autopsy.  In these cases, one was declared dead in the medical 
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tent at the race finish, while the other was certified dead later 
in a local private hospital.
Previous medico-legal autopsy diagnoses after sport-
related deaths in our personal experience in Durban included 
cardiomyopathy, coronary artery disease, Marfan’s syndrome 
and ruptured cerebral berry aneurysms.  It is regrettable that 
autopsies were not performed in the above cases.  Whether 
they should have been considered natural or unnatural may 
be debatable, but postmortem examinations could have 
served to establish the cause/s and mechanism/s of death 
without need for speculation, and before considerations on 
their preventability.  Routine autopsy examinations in such 
instances would enlighten issues of familial/genetic study and 
counselling, scientific research into this area, and for ‘selective 
pre-competition screening’ in sport.
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Pre-analytical, analytical and post- 
analytical considerations in glucose 
point-of-care testing
To the Editor: Point-of-care (POC) blood glucose monitoring 
has become an accepted method to evaluate patients in the 
hospital setting. In most situations, the method is accurate with 
a short turnaround time, which expedites treatment decisions. 
The important issue to keep in mind is that any point of care 
test is subject to pre-analytical, analytical and post-analytical 
variability. 
A case in point: a neonate who presented with prolonged 
jaundice, liver dysfunction (elevated transaminase, 
coagulopathy), and renal tubular dysfunction (normal anion 
gap metabolic acidosis and glucosuria), was treated with 
insulin after POC glucose values were reported to be above 15 
mmol/l. When the patient’s condition deteriorated, the POC 
glucose results were correlated with the laboratory plasma 
glucose concentrations done on the Beckman LX, using a 
glucose oxidase ion selective electrode method. The laboratory 
values were consistently low (discrepant to POC values). The 
urine showed 4+ galactose and the red cells showed reduced 
galactose-1-phosphate uridyl transferase (GALT) activity. The 
patient was diagnosed with galactosaemia. 
POC blood glucose meters have evolved rapidly and 
new-generation meters can exclude many of the previously 
encountered pre-analytical problems including inadequate 
sample volume, improper application and timing, removal of 
excess blood and lockout function if controls are out of range. 
Variables that may influence the analytical process include 
the haematocrit, environmental temperature or humidity, 
hypoxia, high triglyceride concentrations, and inaccuracy 
at very high and very low concentrations.1 Method-specific 
interferences are also encountered, e.g. the POC device in this 
case (Roche Accu-Check Active) is a glucose dehydrogenase 
pyrroloquinolinequinone (GDH-PQQ)-based glucose 
measuring system. This system is not specific for glucose 
and may give false elevated glucose values in the presence 
of maltose, xylose or galactose (Accu-Check Active test strips 
package insert).  Post-analytical factors that influence the 
interpretation of the result are whether a plasma or serum 
value is reported and the unit in which the result is reported. 
Recently, an International Federation of Clinical Chemistry 
(IFCC) working group recommended that all meters must 
be harmonised to the concentration of glucose in plasma, 
irrespective of the type of sample used.1,2
When a POC device is used, the clinician should always 
familiarise himself with the test method and the influence 
of possible interferences on the method. Methods using 
glucose dehydrogenase with NAD as co-factor (GDH-NAD), 
hexokinase or glucose oxidase are specific for glucose and do 
not exhibit interference as a result of interfering sugars.3
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Hypertension: Holding on to your ACEs 
may be a good bet
To the Editor: The recently published South African 
Hypertension Guideline1 provides a comprehensive review 
of the causes and risks of abnormal blood pressure and 
of its treatment, but falls short of offering a cost-effective 
approach to managing the burden. Understanding the causes 
of hypertension, the morbidity associated with it, and the 
effective treatments are necessary, but not sufficient, conditions 
for a cost-effective programme.2,3 Also, adding to the debate, 
one has to look at this from another perspective.
In clinical practice, it is often assumed that angiotensin 
receptor blockers (ARBs) and angiotensin-converting enzyme 
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